Company Overview
Concord Medical Services Holdings Limited operates a specialized network of radiotherapy and diagnostic imaging centers located within the People's Republic of China, serving patients through its distinct Network and Hospital segments. The company's core services encompass the deployment of linear accelerators and external beam radiotherapy, positioning it within the broader Healthcare sector under the specific industry classification of Medical Care Facilities. This entity maintains a workforce of 595 employees and holds a market capitalization of $16.76M, which serves as a key indicator of its current valuation in the public markets. The annualized revenue reported over the trailing twelve months stands at $365.76M, a figure that, when combined with the relatively small market cap, suggests a significant discrepancy between operational scale and market valuation. This structural difference often indicates a market that has priced the company based on specific financial distress factors rather than traditional operational growth metrics, highlighting the severe challenges currently impacting its financial reporting and investor perception.
Financial Health
The company reported a total revenue of $365.76M for the trailing twelve months, yet it simultaneously recorded a net income of $-163,120,000 and an EBITDA of $-356,785,504, revealing a profound disconnect between top-line activity and bottom-line profitability. The substantial gap between the $365.76M in revenue and the negative net income underscores a cost structure where expenses, likely including debt servicing and operational overhead, far exceed gross margins, resulting in an operating margin of -72.1% and a profit margin of -44.6%. Furthermore, the gross margin stands at -11.4%, indicating that the cost of goods sold is exceeding the revenue generated from services, which is an anomalous metric typically signaling severe pricing pressures or cost overruns. Regarding liquidity, the company holds $177.39M in cash, which appears sufficient to cover immediate obligations on the surface, but this is contrasted by a massive debt load of $3.82B, creating a debt-to-equity ratio of 221.98. This high leverage is reflected in the current ratio of 0.42, a figure well below the standard threshold of 1.0, which indicates that the company's short-term assets are insufficient to cover its short-term liabilities without refinancing or asset sales. Additionally, the return on equity is -29.0% and the return on assets is -4.5%, metrics that clearly demonstrate that management is currently destroying shareholder value rather than generating returns, as the company operates at a significant loss relative to its asset base and equity capital.
Valuation Assessment
The valuation metrics for Concord Medical Services Holdings Limited present a complex picture defined by negative multiples, with a trailing P/E ratio listed as N/A due to the absence of positive earnings and a forward P/E of -25.73. The price-to-book ratio is recorded at -0.05, a negative figure that mathematically indicates the market capitalization is less than the book value of equity, suggesting the market is pricing in a scenario where the company's assets are not being fully utilized or that significant liabilities are not fully reflected on the balance sheet. The price-to-sales ratio stands at 0.05, while the EV/EBITDA is -22.74, both of which are alternative valuation measures that typically become distorted when a company is generating negative earnings and negative cash flows. In terms of trading range, the stock has seen its 52-week high at $10.77 and its 52-week low at $3.18, meaning the current price sits at a level that reflects a contraction from the yearly peak, although the exact percentage distance requires the current price input which is not explicitly stated in the facts provided, only the range limits. The beta value of -1.23 is an exceptional statistic that suggests the stock price moves inversely to the broader market, implying a level of volatility and risk profile that is distinct from typical healthcare equities, where a negative beta indicates a counter-cyclical behavior or extreme sensitivity to specific sector-specific negative sentiment.
Growth & Income
The company experienced a revenue growth rate of -8.3% year-over-year, while earnings growth is listed as N/A due to the persistent losses, indicating that the company is contracting in terms of top-line sales and failing to generate positive earnings to support growth narratives. Since the company is not a dividend payer, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not return cash to shareholders, instead retaining any minimal positive cash flows or utilizing existing cash reserves to service its $3.82B debt burden. The absence of a dividend yield means the total return profile for investors is derived solely from capital appreciation or depreciation, which, given the negative operating margins and high leverage, presents a challenging income profile. Overall, the growth and income profile is characterized by revenue contraction, negative earnings expansion, and a complete lack of dividend distribution, reflecting a business currently in a financial distress phase where capital preservation is the primary constraint rather than expansion or income generation.